Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Utilizing Redox Modulation via Novel Catalytic Antioxidants to Promote Beta Cell Health and Survival
EF 2013-14
Résumé
The purpose of this research project is to test a novel biological target and pathway that may improve human beta cell survival in both newly diagnosed type I diabetic (T1D) patients and diabetic recipients of an islet allograft. Redox modulation, through potent catalytic antioxidants (CA), appears to have profound therapeutic potential and may serve to improve the efficiency of islet transplantation as a therapeutic treatment.
The scope of this proposed research will examine the following:
i.Impact of redox modulation via antioxidants to attenuate disease onset and progression in the NOD mouse model
ii.Effects of redox modulation on human islet culture as a means to improve islet recovery, health, potency and clinical transplant outcome
iii.Utilize the pancreata and islets from donation after cardiac death (DCD) donors following therapeutic redox modulation intervention.
We hypothesize that redox modulation, through catalytic antioxidant therapy, will promote beta cell health and survival, and delay or abrogate the progression of disease in the newly diagnosed Type I diabetic patient.
Oxidative stress is a mechanism associated with disease states marked by inflammatory processes, including, but not limited to autoimmune diseases and islet graft dysfunction. Oxidative stress is initiated by the excessive production of reactive oxygen species (ROS) which are potent induces of pro-inflammatory stress responses often marked by proinflammatory cytokines (TNF- a, IL-1b, IL-6, and IFN-g) and chemokine synthesis. Oxidative metabolism is a crucial part of cellular metabolism, and as a result, free radical production is common in these diseases. ROS can function as signaling molecules and inducers of signaling pathways in many cell types, in addition to their many roles of mediating oxidative damage, physiological responses and against microbial pathogens in immunity. A nontoxic, cell-permeable CA may depress free radical and cytokine production by antigen-presenting cells and T cells in transgenic and allospecific mouse models. Recently, Piganelli et al demonstrated that pre-treatment of human islets with a potent CA, promoted robust in vivo function when islets were transplanted as minimal mass. Thus, islet-sparing agents, which decrease the production of free radicals and, therefore, inflammatory cytokines, may have a positive impact on islet function post-transplant and reduced the prevalence of primary non-function, in addition to utilizing islet isolated from DCD pancreata.
If successful, this work will potentially improve the safety and efficiency of engraftment of human islet transplantation, will provide a unique opportunity to develop minimal immunosuppressive and tolerance approaches for islet implantation. Most importantly, this may work will open up an accelerated avenue for future clinical evaluation of catalytic antioxidants to ameliorate disease progression in early onset of diabetes, potentially reducing the inflammatory-mediated injury to the patient’s endogenous beta cell mass. Other benefits include, but are not limited to, improvement of engrafted islets and long-term insulin independence from the current standard-of-care and increased efficiency and survival of islets allowing use of the majority of pancreata which are currently rejected for portal vein delivery. The benefit of the latter would increase the number of patients that could be provided islet transplants and utilize the pancreata and islets from donation after cardiac death (DCD) donors.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311820
Name
Bruni Antonio
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Utilizing Redox Modulation via Novel Catalytic Antioxidants to Promote Beta Cell Health and Survival
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Catalytic Antioxidants; Cell Death; Diabetes Mellitus; Engraftment; Inflammation; Islets And Beta Cell Health; Oxidative Stress; Redox Modulation; Transplantation; Viability
Abstract
The purpose of this research project is to test a novel biological target and pathway that may improve human beta cell survival in both newly diagnosed type I diabetic (T1D) patients and diabetic recipients of an islet allograft. Redox modulation, through potent catalytic antioxidants (CA), appears to have profound therapeutic potential and may serve to improve the efficiency of islet transplantation as a therapeutic treatment.
The scope of this proposed research will examine the following:
i.Impact of redox modulation via antioxidants to attenuate disease onset and progression in the NOD mouse model
ii.Effects of redox modulation on human islet culture as a means to improve islet recovery, health, potency and clinical transplant outcome
iii.Utilize the pancreata and islets from donation after cardiac death (DCD) donors following therapeutic redox modulation intervention.
We hypothesize that redox modulation, through catalytic antioxidant therapy, will promote beta cell health and survival, and delay or abrogate the progression of disease in the newly diagnosed Type I diabetic patient.
Oxidative stress is a mechanism associated with disease states marked by inflammatory processes, including, but not limited to autoimmune diseases and islet graft dysfunction. Oxidative stress is initiated by the excessive production of reactive oxygen species (ROS) which are potent induces of pro-inflammatory stress responses often marked by proinflammatory cytokines (TNF- a, IL-1b, IL-6, and IFN-g) and chemokine synthesis. Oxidative metabolism is a crucial part of cellular metabolism, and as a result, free radical production is common in these diseases. ROS can function as signaling molecules and inducers of signaling pathways in many cell types, in addition to their many roles of mediating oxidative damage, physiological responses and against microbial pathogens in immunity. A nontoxic, cell-permeable CA may depress free radical and cytokine production by antigen-presenting cells and T cells in transgenic and allospecific mouse models. Recently, Piganelli et al demonstrated that pre-treatment of human islets with a potent CA, promoted robust in vivo function when islets were transplanted as minimal mass. Thus, islet-sparing agents, which decrease the production of free radicals and, therefore, inflammatory cytokines, may have a positive impact on islet function post-transplant and reduced the prevalence of primary non-function, in addition to utilizing islet isolated from DCD pancreata.
If successful, this work will potentially improve the safety and efficiency of engraftment of human islet transplantation, will provide a unique opportunity to develop minimal immunosuppressive and tolerance approaches for islet implantation. Most importantly, this may work will open up an accelerated avenue for future clinical evaluation of catalytic antioxidants to ameliorate disease progression in early onset of diabetes, potentially reducing the inflammatory-mediated injury to the patient’s endogenous beta cell mass. Other benefits include, but are not limited to, improvement of engrafted islets and long-term insulin independence from the current standard-of-care and increased efficiency and survival of islets allowing use of the majority of pancreata which are currently rejected for portal vein delivery. The benefit of the latter would increase the number of patients that could be provided islet transplants and utilize the pancreata and islets from donation after cardiac death (DCD) donors.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bruni, Antonio
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~